Agenus vs Regenxbio
AGEN and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGEN and RGNX compare
Regenxbio is the larger company, worth 1.6 times as much as Agenus ($483M against $303M).
Agenus grew revenue faster over the last twelve months (30.5% versus 12.0% for Regenxbio).
Regenxbio scores higher on the StockData Score (4 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGEN | RGNX |
|---|---|---|
| Size and price | ||
| Market cap | $303M | $483M |
| Share price | $6.73 | $7.32 |
| Change, 1 year | 51.9% | −37.1% |
| Change, 5 years | −90.4% | −76.4% |
| Beta (5Y) | – | 2.62 |
| Employees | 81 | 371 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× (better) | 2.8× |
| P/B | – | 6.7× |
| EV/EBITDA | 7.5× | – |
| FCF yield | −32.5% (better) | −51.7% |
| Growth | ||
| Revenue growth (TTM) | 30.5% (better) | 12.0% |
| Revenue growth, 5Y average | 5.3% (better) | 2.0% |
| Profitability | ||
| Gross margin | 99.5% | – |
| Operating margin | 27.3% (better) | −94.1% |
| Net margin | – | −113% |
| FCF margin | −74.2% (better) | −143% |
| Return on equity | – | −138% |
| Financial health | ||
| Net debt / EBITDA | 0.28 | – |
| Interest coverage | 0.6× (better) | −3.9× |
| Current ratio | 0.34 | 2.86 (better) |
| Altman Z-score | −16.50 | −3.87 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 31.7% | 64.2% |
| Held by insiders | 6.6% | 7.6% |
| Insider net buying, 12 months | – | $9.6K |
| Short interest, % of float | 18.1% | 16.7% |
Go deeper
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
- RGNX stock overview
- RGNX income statement
- RGNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.